1 March 2014 - The March 2014 update to the New Zealand Pharmaceutical Schedule is out and nowin effect. The only major change is the widening of the Special Authority for eltrombopag olamine (Revolade) to include patients with a platelet countof 20,000 to 30,000 platelets per microlitreand significant mucocutaneous bleeding.

For more details, go to: http://www.pharmac.govt.nz/2014/02/20/SU.pdf